Loading...
  • Lymphocyte
  • It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. (bioportfolio.com)
  • Ligand
  • It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. (creative-biolabs.com)
  • antitumor activity
  • This approach is intended to spare non-targeted cells and thus may help minimize the potential toxic effects of traditional chemotherapy while allowing for the selective targeting of CD30-expressing cancer cells, thus potentially enhancing the antitumor activity. (drugs.com)
  • CD28
  • We conducted a phase I dose escalation study in which 9 patients with relapsed/refractory HL or ALCL were infused with autologous T cells that were gene-modified with a retroviral vector to express the CD30-specific CAR (CD30.CAR-Ts) encoding the CD28 costimulatory endodomain. (jci.org)
  • Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines. (semanticscholar.org)
  • CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins which are expressed on antigen-presenting cells(APC). (creative-biolabs.com)
  • tumor cells
  • Specific genetic modifications of the anti-CD30 CAR ensure the specific targeting of CD30+ tumor cells and prevent unwanted side-effects. (innovations-report.com)
  • The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells. (drugs.com)
  • targets
  • Kadcyla, which targets the HER2 antigen, is being evaluated in seven Phase III clinical trials, as well as in earlier-stage trials. (drug-dev.com)
  • CELLS
  • In vivo experiments provided evidence that the treatment with anti-CD30 T-cells has no unwanted impact on the endogenous immune system. (innovations-report.com)
  • Although CD30 may also be expressed by normal activated T cells, no patients developed impaired virus-specific immunity. (jci.org)
  • It was first recognized by Stein et al 1 in 1985, who reported the consistent expression of the Ki-1 antigen (later designated CD30) in tumors with frequent cohesive proliferation of large pleomorphic cells. (bloodjournal.org)
  • Its restricted expression on normal cells makes CD30 an attractive candidate for targeted therapy. (drug-dev.com)
  • malignancy
  • All other therapy for malignancy was discontinued at least 4 weeks before CD30.CAR-T infusion. (jci.org)
  • Gene
  • CHO-Anti-Human CD30 F(ab) stable cell line is clonally-derived from a CHO cell line, which has been transfected with an anti-human CD30 F(ab) gene to allow expression of the F(ab). (creativebiomart.net)
  • patients
  • Of 7 patients with relapsed HL, 1 entered complete response (CR) lasting more than 2.5 years after the second infusion of CD30.CAR-Ts, 1 remained in continued CR for almost 2 years, and 3 had transient stable disease. (jci.org)
  • Of 2 patients with ALCL, 1 had a CR that persisted 9 months after the fourth infusion of CD30.CAR-Ts. (jci.org)
  • CD30.CAR-Ts are safe and can lead to clinical responses in patients with HL and ALCL, indicating that further assessment of this therapy is warranted. (jci.org)
  • peripheral
  • CD30.CAR-T expansion in peripheral blood peaked 1 week after infusion, and CD30.CAR-Ts remained detectable for over 6 weeks. (jci.org)
  • cell
  • CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival. (semanticscholar.org)
  • year
  • This graph shows the total number of publications written about "Antigens, CD30" by people in this website by year, and whether "Antigens, CD30" was a major or minor topic of these publications. (wakehealth.edu)